MRTX
Price:
$58.7
Market Cap:
$4.12B
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The c...[Read more]
Industry
Biotechnology
IPO Date
2013-07-15
Stock Exchange
NASDAQ
Ticker
MRTX
According to Mirati Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -61.91%. This represents a change of 198.01% compared to the average of -20.77% of the last 4 quarters.
The mean historical ROE of Mirati Therapeutics, Inc. over the last ten years is -88.27%. The current -61.91% ROE has changed -29.86% with respect to the historical average. Over the past ten years (40 quarters), MRTX's ROE was at its highest in in the September 2021 quarter at -7.38%. The ROE was at its lowest in in the June 2014 quarter at -228.27%.
Average
-88.27%
Median
-55.20%
Minimum
-204.26%
Maximum
-26.30%
Discovering the peaks and valleys of Mirati Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 245.29%
Maximum Annual ROE = -26.30%
Minimum Annual Increase = -71.43%
Minimum Annual ROE = -204.26%
| Year | ROE | Change |
|---|---|---|
| 2022 | -74.35% | 78.53% |
| 2021 | -41.64% | 58.32% |
| 2020 | -26.30% | -52.85% |
| 2019 | -55.78% | 14.25% |
| 2018 | -48.82% | -0.67% |
| 2017 | -49.15% | -71.43% |
| 2016 | -172.05% | 215.02% |
| 2015 | -54.62% | -64.91% |
| 2014 | -155.67% | -23.79% |
| 2013 | -204.26% | 245.29% |
The current ROE of Mirati Therapeutics, Inc. (MRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-47.43%
5-year avg
-49.38%
10-year avg
-88.27%
Mirati Therapeutics, Inc.’s ROE is less than Opthea Limited (44.23%), greater than SpringWorks Therapeutics, Inc. (-35.72%), greater than CymaBay Therapeutics, Inc. (-64.17%), greater than Alpine Immune Sciences, Inc. (-12.69%), less than RayzeBio, Inc. Common Stock (82.72%), greater than MorphoSys AG (-183.80%), greater than Morphic Holding, Inc. (-29.08%), greater than Chinook Therapeutics, Inc. (-41.23%), less than Myovant Sciences Ltd. (49.79%), greater than IVERIC bio, Inc. (-39.26%),
| Company | ROE | Market cap |
|---|---|---|
| 44.23% | $4.24B | |
| -35.72% | $3.54B | |
| -64.17% | $3.73B | |
| -12.69% | $4.46B | |
| 82.72% | $3.75B | |
| -183.80% | $2.86B | |
| -29.08% | $2.86B | |
| -41.23% | $2.71B | |
| 49.79% | $2.62B | |
| -39.26% | $5.51B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mirati Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mirati Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Mirati Therapeutics, Inc.'s ROE?
How is the ROE calculated for Mirati Therapeutics, Inc. (MRTX)?
What is the highest ROE for Mirati Therapeutics, Inc. (MRTX)?
What is the 3-year average ROE for Mirati Therapeutics, Inc. (MRTX)?
What is the 5-year average ROE for Mirati Therapeutics, Inc. (MRTX)?
How does the current ROE for Mirati Therapeutics, Inc. (MRTX) compare to its historical average?